Title |
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease |
|---|---|
Involved |
Jonas S. Heitmann (Verfasser)
Richard Friedrich Schlenk (Verfasser) Daniela Dörfel (Verfasser) Sabine Kayser (Verfasser)
Konstanze Döhner (Verfasser)
Michael Heuser (Verfasser) Felicitas Thol (Verfasser) Silke Kapp-Schwoerer (Verfasser) Jannik Labrenz (Verfasser) Dominic Edelmann (Verfasser) Melanie Märklin (Verfasser) Wichard Vogel (Verfasser) Wolfgang Andreas Bethge (Verfasser) Juliane S. Walz (Verfasser) Ludger Große-Hovest (Verfasser) Martin Steiner (Verfasser) Gundram Jung (Verfasser) Helmut R. Salih (Verfasser) SpringerLink (Online service) (Sonstige) |
Published in |
Journal of hematology & oncology 16, 1, 17.8.2023, date:12.2023, Seite 1-9 |
Published |
2023 |
Language |
|
Country |
|
Topic |
|
Subject |
Oncology. |
DDC notation |
|
Persistent identifier |
urn:nbn:de:101:1-2023110413302238239858 (URN) |
Record ID |
1308596154 |
Please note
The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link: